Weiner George J
Department of Medicine and The Graduate Program in Immunology, The University of Iowa, Iowa City, IA, USA.
Immunol Res. 2007;39(1-3):271-8. doi: 10.1007/s12026-007-0073-4.
Monoclonal antibodies (mAbs) are used extensively as treatment for cancer. A variety of mechanisms are thought to play important roles in mediating the observed anti-tumor effects of mAb. These include signaling mediated by cross-linking of surface antigen that leads to cell death, blocking an activation signal that is necessary for continued cell growth, antibody-dependent cellular cytotoxicity (ADCC), complement mediated cytotoxicity (CMC) and the ability of mAb to alter the cytokine milieu or enhance development of an active anti-tumor immune response. In this review the in vitro, animal model and clinical results supporting each of these varied mechanisms is summarized as is the potential for these mechanisms to interact with each other.
单克隆抗体(mAb)被广泛用作癌症治疗药物。人们认为多种机制在介导单克隆抗体所观察到的抗肿瘤作用中发挥重要作用。这些机制包括由表面抗原交联介导的信号传导,该信号传导导致细胞死亡;阻断持续细胞生长所必需的激活信号;抗体依赖性细胞毒性(ADCC);补体介导的细胞毒性(CMC);以及单克隆抗体改变细胞因子环境或增强活性抗肿瘤免疫反应发展的能力。在本综述中,总结了支持这些不同机制的体外、动物模型和临床结果,以及这些机制相互作用的可能性。